Effect of Molnupiravir on Biomarkers, Respiratory Interventions, and Medical Services in COVID-19 : A Randomized, Placebo-Controlled Trial코로나19의 바이오마커, 호흡기 중재 및 의료 서비스에 대한 몰누피라비르의 효과 : 무작위, 위약 대조 시험Randomized Controlled Trial Published on 2022-08-012022-09-11 Journal: Annals of internal medicine [Category] COVID19(2023년), MERS, SARS, 바이오마커, 임상, [키워드] 95% CI Analysis assigned baseline benefit C-reactive protein C-reactive protein (CRP Care change clinical benefit clinically Concentration COVID-19 CRP death discharge discharged double-blind Effect evaluated faster Hospitalization Hospitalized identify immunized improvement Improvements Inc Invasive mechanical ventilation less LLC median medical service medical services Mild mild to moderate Mild to moderate COVID-19 Moderate COVID-19 molnupiravir Older oxygen oxygen saturation participant performed Phase 3 Placebo placebo-controlled placebo-treated participant placebo-treated participants potential clinical benefit progression randomization Randomized Randomly receiving reduction in Relative risk respiratory respiratory intervention respiratory interventions risk risk factor Risk factors risk reduction SARS-CoV-2 secondary service severe disease Sharp subsidiary therapy Trial [DOI] 10.7326/M22-0729 PMC 바로가기 [Article Type] Randomized Controlled Trial
Developing New Treatments for COVID-19 through Dual-Action Antiviral/Anti-Inflammatory Small Molecules and Physiologically Based Pharmacokinetic Modeling이중 작용 항바이러스/항염 소분자 및 생리학적 기반 약동학 모델링을 통한 COVID-19에 대한 새로운 치료법 개발Review Published on 2022-07-202022-09-11 Journal: International Journal of Molecular Sciences [Category] COVID19(2023년), SARS, 진단, 치료제, [키워드] (dexamethasone Anti-inflammatory Anti-SARS-CoV-2 Activity Antiviral antiviral agent Antiviral agents approach Baricitinib biochemical pathway Biochemical pathways characterization COVID-19 COVID-19 pandemic Critical Cytopathic effect develop Developing Dexamethasone drug target dual dual action early treatment effective Efficacy and safety health system health systems High-risk patients identify in silico in vitro in vivo model Infection inflammatory cascade inhibitor inhibitors mechanism Mild mild to moderate Mild to moderate COVID-19 modeling Moderate COVID-19 molecular docking molecule molnupiravir monoclonal antibodies multidisciplinary approach New Nirmatrelvir pandemic pathogen PBPK modeling pharmacological protocol Ritonavir therapeutic agent therapeutic agents threat Treatment treatment of COVID-19 Viral virus viruses [DOI] 10.3390/ijms23148006 PMC 바로가기 [Article Type] Review
Use of combined treatment of 3rd-generation cephalosporin, azithromycin and antiviral agents on moderate SARs-CoV-2 patients in South Korea: A retrospective cohort study한국에서 중등도 SARs-CoV-2 환자에 대한 3세대 세팔로스포린, 아지트로마이신 및 항바이러스제 병용 치료: 후향적 코호트 연구Article Published on 2022-05-042022-09-11 Journal: PLoS ONE [Category] COVID19(2023년), SARS, 치료제, [키워드] adjust administration adverse event Analysis analyzed Antibiotics antiviral agent Antiviral agents association Azithromycin baseline characteristics cephalosporin Clinical outcome Cohort cohorts Combined combined treatment conducted confounding factors COVID-19 COVID-19 patient Cox regression analysis Cox regression method death Efficacy and safety Endpoint endpoints Evidence groups hazard ratio hazard ratios Hospital stay Hydroxychloroquine inclusion criteria Kaplan-Meier Kaplan-Meier curve Kaplan-Meier curves laboratory-confirmed Lopinavir Lopinavir/ritonavir low-dose mild to moderate Mild to moderate COVID-19 moderate Moderate COVID-19 moderate COVID-19 patients no significant difference no significant differences not significant Patient performed Prevent Propensity score propensity score matching PSM retrospective cohort study Ritonavir SARS-CoV-2 SARS-CoV-2 patient SARS-CoV-2 patients significant differences South South Korea Standard standard supportive care statistical significance Supportive treatment symptom resolution Time to symptom resolution Treatment treatment arm treatment group viral clearance were used [DOI] 10.1371/journal.pone.0267645 PMC 바로가기 [Article Type] Article
Rates of Severe Outcomes After Bamlanivimab-Etesevimab and Casirivimab-Imdevimab Treatment of High-Risk Patients With Mild to Moderate Coronavirus Disease 20192019년 경증에서 중등도의 코로나바이러스 질환이 있는 고위험 환자의 밤라니비맙-에테세비맙 및 카시리비맙-임데비맙 치료 후 심각한 결과의 비율Article Published on 2022-05-012022-09-11 Journal: Mayo Clinic proceedings [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] 95% CI acute respiratory syndrome acute respiratory syndrome coronavirus Alpha bamlanivimab Casirivimab Clinical characteristics Clinical efficacy Clinical outcome clinical outcomes clinical study Cohort cohorts of patient coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 demographic and clinical characteristics drug Efficacy emergency treatment etesevimab food higher odd higher odds Hospitalization Imdevimab Mild mild to moderate Mild to moderate COVID-19 moderate Moderate COVID-19 monoclonal antibodies monoclonal antibody not significantly different observation Odds ratio outcome oxygen oxygen supplementation Patient progression Rate reason respiratory Retrospective study severe acute respiratory syndrome Coronavirus significant difference significantly higher treated Treatment US Food and Drug Administration variants wild-type [DOI] 10.1016/j.mayocp.2022.02.009 PMC 바로가기 [Article Type] Article
Predictors of post-COVID symptoms in Egyptian patients: Drugs used in COVID-19 treatment are incriminated이집트 환자의 코로나 후 증상 예측자: COVID-19 치료에 사용된 약물은 유죄Article Published on 2022-03-312022-09-11 Journal: PLoS ONE [Category] SARS, 치료기술, [키워드] age Antibiotics Comorbidities Corticosteroid Corticosteroids COVID-19 Critical cross-sectional survey described disease drug Factor fatigue females followed by form Google indicated Infection intake International knowledge Mild mild to moderate Mild to moderate COVID-19 Moderate COVID-19 MOST participant Patient physical predictor presence of comorbidities Prevalence psychological symptom regression analysis severe Sex significantly Symptom Symptoms syndrome the disease these symptoms took place Treatment use of antibiotics was used [DOI] 10.1371/journal.pone.0266175 PMC 바로가기 [Article Type] Article
Oral famotidine versus placebo in non-hospitalised patients with COVID-19: a randomised, double-blind, data-intense, phase 2 clinical trial입원하지 않은 COVID-19 환자의 경구 파모티딘 대 위약: 무작위, 이중 맹검, 데이터 집약적, 2상 임상 시험Clinical Trial Published on 2022-02-092022-09-10 Journal: Gut [Category] COVID19(2023년), SARS, 임상, 진단, 치료기술, 치료법, [키워드] 95% CI adult outpatient adverse event African American anti-SARS-CoV-2 ARMS baseline clinical trial clinical trials core protein COVID-19 detectable difference double-blind endpoints Estimated Ethnicity exploratory Famotidine Fewer patients Hispanic Immunity Immunoglobulin independent independent of Inflammation intention-to-treat interferon Interferon alpha median age Mild mild to moderate Mild to moderate COVID-19 Moderate COVID-19 non-hospitalised objective occurred oral Outpatient outpatients Patient Phase 2 Placebo placebo-controlled plasma Protein randomised Randomised trial Rate reducing reduction required resolution of symptom Result Safe SARS-CoV-2 nucleocapsid Sex statistically Symptom symptom resolution symptomatic time Time to symptom resolution treat treated patients Trial women [DOI] 10.1136/gutjnl-2022-326952 PMC 바로가기 [Article Type] Clinical Trial
Efficacy of Niclosamide vs Placebo in SARS-CoV-2 Respiratory Viral Clearance, Viral Shedding, and Duration of Symptoms Among Patients With Mild to Moderate COVID-19 A Phase 2 Randomized Clinical Trial경증에서 중등도의 COVID-19 A 2상 무작위 임상 시험에서 SARS-CoV-2 호흡기 바이러스 제거, 바이러스 배출 및 증상 지속 기간에서 니클로사미드 대 위약의 효능Randomized Controlled Trial Published on 2022-02-092022-09-10 Journal: JAMA Network Open [Category] COVID19(2023년), SARS, 신약개발, 임상, 치료제, [키워드] 1:1 95% CI accounted addition adverse event adverse events age All trial participants analyzed antiviral activity assigned blind by mouth calculated center Chain Reaction Characteristics clearance of SARS-CoV-2 clinical clinical trial confirmation contagious period cough COVID COVID-19 COVID-19 testing decrease determined by diagnose Duration duration of symptom Efficacy enrolled Enrollment exclusion criteria fecal Fecal sample finding group groups headache Headaches Hospitalization Importance in vitro individual Infection intention-to-treat investigators Laboratory Massachusett Massachusetts mean difference mean survival time measure men Mild mild to moderate Mild to moderate COVID-19 mild to moderate symptoms moderate Moderate COVID-19 MONITOR mouth network niclosamide no significant difference objective oral Oropharyngeal participant Participants Patient patients receiving placebo Phase 2 Placebo placebo group placebo-controlled clinical trial platform Point polymerase chain polymerase chain reaction positive primary end point proportion Randomized randomized clinical trial Randomly receive receiving Registration Relevance reported respiratory respiratory sample Respiratory samples Result Safe sample collection Sample size SAR-CoV-2 SARS-CoV-2 SARS-CoV-2 clearance setting shedding significant effect significantly Standard of care statistically Symptom symptom duration symptom resolution Symptoms the placebo group therapy treat Treatment treatment for COVID-19 treatment groups Trial trial participants Tuft vaccination Viral viral clearance viral shedding was collected [DOI] 10.1001/jamanetworkopen.2021.44942 PMC 바로가기 [Article Type] Randomized Controlled Trial
Monoclonal antibody treatment for COVID-19 in solid organ transplant recipients고형장기 이식 환자의 코로나19 단일클론항체 치료Article Published on 2022-02-012022-09-11 Journal: Transplant infectious disease : an official journa [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] adverse event adverse events age antibody treatment bamlanivimab biopsy Casirivimab casirivimab-imdevimab circulating viral variant circulating viral variants Comparator group confidence confidence interval coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 symptom COVID-19 symptoms deaths Diabetic diagnosed with COVID-19 eligible emergency department Emergency use authorization Follow-up generally mild high risk High-risk patients Hospitalization Imdevimab infusion interval Intervention IQR kidney kidney transplant liver lung median age median time Mild mild to moderate Mild to moderate COVID-19 Moderate COVID-19 monoclonal monoclonal antibodies monoclonal antibody nine occurred organ Organ transplant outcome Patient patients Ratio receive recipient recipients reduce rejection risk SARS-CoV-2 SARS-CoV-2 spike protein severe coronavirus disease single-center Solid solid organ solid organ transplant SOT Spike protein statistically significant study period the SARS-CoV-2 therapy Transplant treated Treatment two patients Viral Viral variants [DOI] 10.1111/tid.13759 PMC 바로가기 [Article Type] Article
SARS-CoV-2 antibody and T cell responses one year after COVID-19 and the booster effect of vaccination: A prospective cohort study코로나19 1년 후 SARS-CoV-2 항체 및 T 세포 반응과 백신 접종의 부스터 효과: 전향적 코호트 연구Article Published on 2022-02-012022-09-11 Journal: The Journal of Infection [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술, [키워드] Ad26 Ad26.COV2-S Anti-RBD IgG antibody Antibody Response Blood BNT162b2 booster ChAdOx1 ChAdOx1-S comparable Concentration COVID-19 COVID-19 vaccination COVID-19 vaccine detectable first vaccination healthcare worker Healthcare workers IgG IgG response IgG responses immune response immune responses Immunity Immunoglobulin Immunoglobulin G individual individuals infected individuals IQR Mild mild to moderate Mild to moderate COVID-19 Moderate COVID-19 mononuclear cell mononuclear cells mRNA mRNA-1273 PBMCs Peripheral blood Peripheral blood mononuclear cells prospective cohort prospective cohort study RBD IgG response retained SARS-CoV-2 SARS-CoV-2 antibody SARS-COV-2 infection second second vaccination seroconverted spot-forming cell suffered T cell T cell response T cell responses vaccination vaccine-induced immune response vaccine-induced immune responses [DOI] 10.1016/j.jinf.2021.12.003 PMC 바로가기 [Article Type] Article
Risk Factors for Therapeutic Intervention of Remdesivir in Mild to Moderate COVID-19—A Single-Center Retrospective Study of the COVID-19 Fourth Pandemic Period in Wakayama, Japan경증에서 중등도의 COVID-19에서 렘데시비르의 치료적 중재를 위한 위험 요인 - 일본 와카야마에서 발생한 COVID-19 4차 유행기에 대한 단일 센터 후향적 연구Article Published on 2022-01-132022-09-10 Journal: Medicina [Category] SARS, 변종, [키워드] Admission age B.1.1.7 B.1.1.7 variant Clinical characteristics Clinical data contribute coronavirus disease Coronavirus disease 2019 COVID-19 diabetes Diabetes Mellitus Disease progression enrolled Factor Fever group headache hospital Hospital admission Hospitalization Hospitalized incidence independent risk factor independent risk factors intensive care interquartile interquartile range Japan material median medical system Mild mild to moderate Mild to moderate COVID-19 Moderate COVID-19 observation Odds ratio one patient pandemic Patient patients hospitalized Period Remdesivir required respiratory respiratory symptom respiratory symptoms Retrospective study risk factor Risk factors significantly single-center Spread Standard deviation therapeutic intervention transferred Treatment with COVID-19 [DOI] 10.3390/medicina58010118 PMC 바로가기 [Article Type] Article